Serial Urinary Mycotoxin Trends and Clinical Response During Binder Therapy: A Retrospective Case Series

BackgroundDiagnostic approaches for suspected mold-related illness vary widely.Urinary mycotoxin testing is increasingly used in outpatient practice because it is easy to obtain and provides a quantitative marker that can be followed over time, though its interpretation remains controversial.Elevated urinary mycotoxins are often used with symptoms to support case definition and justify binder-based treatment, even when exposure history is uncertain. ObjectiveThe aim of this study is to describe serial urinary mycotoxin results, symptom trajectories, binder exposure, and concurrent interventions in a retrospective observational case series of patients receiving bindercentered care for suspected mold-related illness. MethodsWe performed a retrospective case series of six patients treated in an outpatient integrative medicine setting.All had elevated urinary mycotoxins on RealTime Laboratories (Carrollton, Texas, USA) testing and received binder-based protocols centered on activated charcoal, bentonite clay, and chlorella.Clinical outcomes were assessed using patient-reported global improvement estimates and qualitative follow-up documentation.Urinary mycotoxin testing was repeated over time to evaluate biomarker trends. ResultsUrinary mycotoxin trends were variable and did not consistently correspond with clinical outcomes.Some patients showed reductions despite little meaningful improvement, whereas others improved while urinary trends remained mixed or worsened.Clinical improvement observed during binder-based care was often limited or non-sustained, and several patients remained stable or improved after discontinuing binders. ConclusionsAcross these six cases, urinary mycotoxin trends did not consistently parallel patient-reported symptom trajectories.Clinical improvement during binder-based care was heterogeneous and frequently occurred in the context of other concurrent or subsequent interventions.These observations are descriptive and hypothesis-generating and do not establish the validity of urinary mycotoxin testing or the effectiveness of binder therapy.